Specific inhibition of tenascin-C with Cilostazol attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats

Research Project

Project/Area Number	24592057
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Thoracic surgery
Research Institution	Mie University
Principal Investigator	SHIMPO HIDETO 三重大学, 医学(系)研究科(研究院), 教授 (70179076)
Co-Investigator(Renkei-kenkyūsha)	SHIMAMOTO AKIRA 三重大学, 医学部附属病院, 講師 (90324524) MAESHIRO RYO 三重大学, 医学系研究科, 助教 (90647124) GOTO TAKEHIRO 三重大学, 医学部附属病院, 技術補佐員 (80774877) MATSUO ERI 三重大学, 医学系研究科, 特定事業技術補佐員 (40751665)
Project Period (FY)	2012-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000) Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	肺高血圧 / 細胞外マトリックス / テネイシン / 細胞外マトリクス
Outline of Final Research Achievements	Three weeks after monocrotaline administration to induced pulmonary hypertension (PH), daily treatment of phosphodiesterase inhibitor with Cilostazol significantly reduced mean pulmonary artery (PA) pressure and morphometric changes of PA. Tenascin-C expression were significantly reduced during all periods. We showed that Cilostazol ultimately prevented the progression of PH.